Report: Determined Amgen sweetens its bid for Onyx Pharma August 6, 2013 | By John Carroll
Onyx's campaign to spark a bidding war for the company may be working--at least a little bit. Bloomberg, which has been tracking the blow-by-blow through its sources, says that Amgen ($AMGN) has bumped its offer to $130 a share, up from the original $120 bid that prompted Onyx ($ONXX) to put itself on the auction block.
If accurate, Amgen's not far off the current share price for Onyx, hovering around $132 on Tuesday afternoon. But the news is likely to still be a disappointment for the bulls, who want to see the biotech--valued at around $10 billion--go for a much higher price. Bloomberg adds that the $130 offer is currently the highest bid.
In the weeks since Onyx acknowledged Amgen's bid, reporters at Bloomberg as well as Reuters have identified a few interested bidders. At one point in late July, Novartis ($NVS), Pfizer ($PFE) and AstraZeneca ($AZN)--anxious to grow a weakening sales number--were reportedly interested in a buyout, though Amgen is the only company publicly linked to an Onyx offer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.